All In Biotech

Drug Trial Radar · NCT06780267

Clinical Study of HRS-2129 for Postoperative Analgesia in Orthopaedics

Clinical Study on Safety and Efficacy of HRS-2129 for Postoperative Analgesiain Orthopaedics

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 199 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

199

Actual

Start

Mar 11, 2025

Primary completion

Mar 19, 2026

Study completion Apr 3, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for Postoperative analgesia in orthopaedics. To explore the reasonable dosage of HRS-2129 for Postoperative analgesia in orthopaedics.

Conditions

  • Postoperative Pain in Orthopaedics

Interventions

  • HRS-2129Drug

    HRS-2129

  • HRS-2129 placeboDrug

    HRS-2129 placebo

  • Tramadol Hydrochloride SR TabletsDrug

    Tramadol Hydrochloride SR Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety:Incidence and severity of AE/SAETime frame: from ICF signing date to day 12 since last dose(14 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sichuan Academy of Medical Sciences - Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.